Champions Oncology, Inc.
CSBR Healthcare Biotechnology
Champions Oncology, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $59.4 million, up 4.36% from fiscal 2025. In the quarter to July 2026, revenue grew 8.84%, EPS was flat and free cash flow fell 198.7%, each against the same quarter a year earlier.
Follow CSBR
Champions Oncology, Inc. (CSBR) Altman Z-score
Champions Oncology, Inc.'s Altman Z-score for fiscal 2026 is −0.02, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2026 | −0.02 | (0.78) |
| FY2025 | 0.76 | 3.26 |
| FY2024 | −2.50 | (1.68) |
| FY2023 | −0.82 | (1.81) |
| FY2022 | 0.98 | (1.12) |
| FY2021 | 2.11 | 2.21 |
| FY2020 | −0.10 | (0.63) |
| FY2019 | 0.53 | 7.66 |
| FY2018 | −7.13 | 3.87 |
| FY2017 | −11.01 | 4.66 |
How fiscal 2026’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (0.03) | — | −0.03 | |
| Retained earnings / total assets | (3.00) | — | −4.21 | |
| EBIT / total assets | (0.04) | — | −0.14 | |
| Market value of equity / total liabilities | 3.60 | — | 2.16 | |
| Sales / total assets | 2.20 | — | 2.20 | |
| Altman Z-score | Distress zone | −0.02 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −10.06 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| XBIT XBiotech Inc. compare | 11.7× |
| SPRO Spero Therapeutics, Inc. compare | 1.0× |
| CSBR Champions Oncology, Inc. | 0.0× |
| HYFT MindWalk Holdings Corp. compare | −5.6× |
| VRCA Verrica Pharmaceuticals Inc. compare | −6.7× |
| NMAD Nomad Power Solutions, Inc. compare | — |
| MAIA MAIA Biotechnology, Inc. compare | — |
| CING Cingulate Inc. compare | — |
| OSTX OS Therapies Incorporated compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets